EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Impact of Biologics on Surgery in Chronic Rhinosinusitis with Polyps and Allergic Fungal Sinusitis

Mihai A Bentan iD, Graham Pingree, Lawrance Lee iD, Thomas Fitzpatrick, Theodore Schuman

The Laryngoscope · 2025

DOI: 10.1002/lary.31774 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Laryngoscope, 2025. Verfasst von Mihai A Bentan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology - Head and Neck Surgery, Virginia Commonwealth University Health Systems, Richmond, Virginia, U.S.A. Hauptthemen laut MEDLINE: Sinusitis, Nasal Polyps, Biological Products, Rhinitis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the efficacy of th2‐targeted biologic medications (dupilumab, omalizumab, and mepolizumab) on absolute risk reduction (ARR) of functional endoscopic sinus surgery (FESS) in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and allergic fungal rhinosinusitis (AFRS).

Methods

The TriNetX Research Network database was queried for each mAb's market lifespan through March 2024. Adults with CRSwNP were propensity score matched against non‐mAb controls based on age, sex, race, and asthma diagnosis. The primary outcome was rate of FESS, with secondary outcomes including inpatient admission, emergency department (ED) visit, and incidence of acute sinusitis. Subgroup analysis was performed for patients with AFRS.

Results

All mAbs decreased FESS risk (dupilumab, ARR 11.48%, 95% CI 9.82%–13.15%, p < 0.001; omalizumab, ARR 12.02%, 95% CI 4.36%–19.68%, p = 0.002; mepolizumab, ARR 10.32%, 95% CI 5.24%–15.40%, p < 0.001) in CRSwNP patients. Only dupilumab also reduced risk of inpatient admission (ARR 8.59%, 95% CI 7.04%–10.15%, p < 0.001), ED visit (ARR 5.94%, 95% CI 4.28%–7.61%, p < 0.001), and acute sinusitis (ARR 2.60%, 95% CI 1.09%–4.12%, p = 0.001). In AFRS patients, only dupilumab reduced the risk of all outcomes: FESS (ARR 6.97%, 95 CI 2.86%–11.09%, p = 0.001), inpatient admission (ARR 16.93%, 95% CI 11.30%–22.57%, p < 0.001), ED visit (ARR 13.15%, 95% CI 7.15%–19.14%, p < 0.001), and acute sinusitis (ARR 7.17%, 95% CI 2.18%–12.17%, p = 0.005).

Conclusion

Although all mAbs reduced FESS risk in CRSwNP, only dupilumab reduced secondary outcomes as well. Similarly, only dupilumab improved all outcomes in AFRS patients. These data demonstrate the potential of mAbs in reducing disease burden and enhancing patient outcomes in CRSwNP and AFRS. Level of Evidence NA Laryngoscope , 135:593–601, 2025

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SinusitisNasal PolypsBiological ProductsRhinitisMycosesRhinitis, AllergicHumansMaleFemaleChronic DiseaseMiddle AgedAdultAntibodies, Monoclonal, HumanizedEndoscopyOmalizumabTreatment OutcomeRetrospective StudiesAllergic Fungal SinusitisRhinosinusitis

Stichwörter der Autor:innen

FESSallergic fungal sinusitischronic rhinosinusitisendoscopic sinus surgery

Substanzen

Antibodies, Monoclonal, HumanizedBiological ProductsdupilumabmepolizumabOmalizumab

Autor:innen und Institutionen

  • Department of Otolaryngology - Head and Neck Surgery, Virginia Commonwealth University Health Systems, Richmond, Virginia, U.S.A.
  • Virginia Commonwealth University School of Medicine, Richmond, Virginia, U.S.A.

ORCID-Profile: Mihai A Bentan, Lawrance Lee

Zitieren

APA

Bentan, M. A., Pingree, G., Lee, L., Fitzpatrick, T., & Schuman, T. (2025). Impact of Biologics on Surgery in Chronic Rhinosinusitis with Polyps and Allergic Fungal Sinusitis. The Laryngoscope. https://doi.org/10.1002/lary.31774

Vancouver

Bentan MA, Pingree G, Lee L, Fitzpatrick T, Schuman T. Impact of Biologics on Surgery in Chronic Rhinosinusitis with Polyps and Allergic Fungal Sinusitis. The Laryngoscope. 2025. doi:10.1002/lary.31774

BibTeX
@article{Bentan2025,
  author = {Bentan, Mihai A and Pingree, Graham and Lee, Lawrance and Fitzpatrick, Thomas and Schuman, Theodore},
  title = {Impact of Biologics on Surgery in Chronic Rhinosinusitis with Polyps and Allergic Fungal Sinusitis},
  journal = {The Laryngoscope},
  year = {2025},
  doi = {10.1002/lary.31774}
}
Kostenlos starten →